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Snnlnlal~r 
Clq receptors (ClqR.)  have been identifed on a variety of somatic and cultured ceils including 
peripheral blood platelets. Since platelets are likely to encounter both circulating Clq multimers 
and Clq associated with the extracellular matrix after complement activation  by the classical 
pathway, the present study was designed to assess the effect of fluid phase and immobilized Clq 
on platelet function. Platelet adhesion to Clq-coated surfaces was accompanied by the induction 
of fibrinogen receptors. Scatchard analysis of fibrinogen binding to adherent platelets revealed 
the binding of '~10,000  molecules  of fibrinogen per platelet  with a Ka of 0.1  _+  0.03  /zM 
(mean _+ SD, n =  4). Furthermore, fluid phase Clq multimers were noted to aggregate platelets 
at doses > 5/~g/ml. This aggregation was preceded by a rise in inositol-l,4,5-trisphosphate  (IP3) 
(6.9  _+  2.4  pmoles/109  platelets  at  15  s,  n  =  4),  and activation  of GPIIb-IIIa complexes 
supporting fibrinogen binding. Platelet aggregation in response to Clq multimers was accompanied 
by the aspirin-inhibitable  release of granule contents and P-selectin (CD62) expression. Platelet 
aggregation was inhibited by the collagenous domain of Clq (c-Clq) and a monoclonal antibody 
directed against Clq receptors, suggesting the direct involvement of the 67-kD platelet ClqR. 
Antibodies against the very late antigen 2 or CD36 collagen receptors were without effect. Platelet 
exposure to Clq multimers was also accompanied by the expression of procoagulant activity, 
as demonstrated by the dose-dependent  shortening of the kaolin recalcification time of normal 
plasma from 108  _  12 s in the presence of unstimulated platelets to 62  _+  14 s in the presence 
of platelets that had been preincubated (5 min, 37~  with 100 #g/ml multimeric Clq (n =  3). 
These data suggest that platelet interactions with Clq multimers or immobilized Clq, resulting 
in the activation of GPIIb-IIIa fibrinogen binding sites and the expression of P-selectin as well 
as platelet procoagulant activity, are likely to contribute to thrombotic events associated with 
complement activation  and inflammation. 
C  lq is a 460,000-mol wt glycoprotein present in plasma at 
~,75 #g/ml (1). Clq circulates as a calcium-dependent 
complex with Clr2 and Clsz, forming the first component 
of complement, C1 (2). Upon activation of C1 by circulating 
immune complexes or certain bacteria and viruses, Clr2 and 
Cls2 are disassembled by Cl-inactivator  (3), leaving complex- 
bound Clq with its collagen-like tail exposed and potentially 
available for binding to Clq receptors (ClqR.) (4). Whereas 
the extravascular localization  of free Clq is limited under 
normal conditions,  selective accumulation of this protein 
has been observed in inflamed and injured tissues, particu- 
larly after vascular injury or enhanced vascular permeability 
(5,  6).  Moreover,  the  secretion  of Clq  by  lymphokine- 
activated monocytes or macrophages  has been documented 
(7, 8). 
The interaction of Clq with its receptors on somatic and 
cultured cells has been reported to elicit a variety of biolog- 
ical responses (4). In platelets, the interaction with mono- 
meric Clq was  first  reported to  inhibit collagen-induced 
platelet  aggregation (9, 10). The structural similarities be- 
tween the NH2 terminus of Clq and collagen (11) suggested 
that Clq and collagen binding sites were identical.  Recent 
studies (12), however, have demonstrated the existence of dis- 
tinct platelet membrane receptors for Clq and collagen. Under 
certain conditions, however, these sites demonstrate cross- 
reactivity with regard to ligand binding (12). 
Since virtually all biologically important C1 activating sub- 
stances, including immune complexes, RNA tumor viruses, 
and lipid A-rich LPS bind multiple Clq molecules, Clq is 
likely to circulate in multimeric or aggregated form after ac- 
579  J. Exp.  Med. ￿9  The Rockefeller  University Press ￿9 0022-1007/93/08/0579/09  $2.00 
Volume  178  August 1993  579-587 tivation of the classical complement pathway (13, 14). Un- 
like Clq monomers, Clq muhimers have been suggested to 
support platelet aggregation (9). Because Clq has also been 
reported as a transient component of the extraceUular matrix 
(15), the present study was designed to evaluate the response 
of platelets both to Clq muhimers in the fluid phase,  and 
to immobilized Clq on plastic surfaces. 
Materials and Methods 
Platelet Preparation 
Blood was collected from human volunteers after obtaining in- 
formed consent. The blood was anticoagulated with 0.1 vol 3.2% 
sodium citrate in the presence or absence of I mM aspirin. Platelet- 
rich plasma (PRP) was prepared by centrifugation of whole blood 
at 280 g (15 rain, 22~  Washed platelets (WP) t were obtained 
after acidifying  the PRP to pH 6.5 with 1 M dtric acid, centrifuging 
the sample (1,000 g, 20 min, 22~  and resuspending  the resulting 
platelet pellet in 0.01 M Hepes-buffered  modified Tyrode's  solution 
containing no added calcium, 2 mM MgClz, and 2 mg/ml BSA 
(HBMT) (Sigma Chemical Co., St. Louis, MO) (16). 
Purification  of Protein  Ligands 
Clq was isolated from human serum as described  by Reid (17). 
Digestion of Clq with pepsin to obtain the coUagen-like  domain 
(c-Clq) was performed as previously described (18). Purified Clq 
(1 rag/m1) in 0.23 M sodium acetate buffer, pH 5.2, was dialyzed 
against 0.01 M PBS, pH 7.2, for 48 h at 4~  The resulting mate- 
rial appeared cloudy and was designated  muhimeric/aggregated  Clq 
(agg-Clq). To rule out effects of bacterial contamination of agg- 
Clq preparations during dialysis, similar studies were performed 
using microfihered (0.2/~m) Clq, autoclaved  dialysis  buffers, and 
glassware. Sterile  agg-Clq supported similar dose-dependent  phtelet 
activation as nonsterile preparations (data not shown). Aggregated 
IgG (agg-IgG) was prepared by heat treatment (60~  20 min) 
of  protein A-purified,  human IgG. Agg-lgG was tested  for its ability 
to activate complement by hemolytic assay (19). Fibrinogen was 
purified from fresh frozen plasma (20) and iodinated with lzsI and 
an immobilized  oxidant (N-chlorobenzenesulfonamide  : iodobeads; 
Pierce Chemical Co., Rockford, IL) according to the instructions 
provided by the manufacturer. 
Antibodies to the 67-kD ClqR designated II1/D1 were purified 
from ascites (21). mAbs recognizing the very late antigen (VLA) 
2 collagen receptor (6F1) (22) were obtained as a gift from Dr. 
B. Coller, State University of New York (SUNY) at Stony Brook. 
mAbs (IOP36) against CD36,  platelet glycoprotein IV (GPIV), 
were purchased from AMAC, Inc. (Westbrook, ME). 
Preparation  of Protein-coated Surfaces 
Microtiter wells were exposed to purified Clq (80/~g/ml)  or 
BSA (80/zg/ml) for 16 h at 4~  Unreactive sites were blocked 
for 60 n'fin  at 37~  with 0.1% BSA. Wells  were rinsed with HBMT 
before exposure to platelets. 
Platelet Function  Studies 
PlateletAggregation.  Phtelet aggregation  was monitored at 37~ 
in a dual channel aggregometer (Chronolog Corp., Havertown, 
1 Abbreviations used in this paper: agg, aggregated;  GPIV, glycoprotein  IV; 
IP3, inositol-l,4,5-triphosphate;  PF3, platelet factor 3; VLA, very late 
antigen; WP, washed platelet. 
PA) after addition of 5-100/~g/ml agg-Clq. In some experiments, 
platelets were preincubated (5 min, 22~  with c-Clq (100/~g/ml) 
or mAbs, II1/I)1, 6F1, IOP36 (20/~g/ml)  directed  against  the ClqR, 
the VLA-2  collagen  receptor, or the CD36/GPW collagen  receptor, 
respectively. In other experiments, platelets  were preincubated with 
mAbs (50  /~g/ml), recognizing  the  platelet  Fc3~RII receptor 
(AMAC, Inc.), before exposure to agg-Clq. 
Fitm'nogen Binding to WP Suspensions.  Fibrinogen binding to 
WP was evaluated  in an unstirred system (20) after platelet stimu- 
lation with agg-Clq in the presence of increasing amounts of l~I- 
fibrinogen. Nonspecific  binding was assessed  in the presence of 10 
mM EDTA or excess unlabeled fibrinogen (20). 
Fibrinogen Binding to Adherent Platelets.  WP (1.25  x  107) were 
added to Clq-coated microtiter  wells. After 30-min adhesion  (22~ 
nonadherent ptatelets were removed, the wells rinsed three times 
with PBS, and platelet adhesion quantified in duplicate wells using 
the bicinchoninic acid protein assay  (23). Additional wells were ex- 
posed to increasing  concentrations of l~sI-fibrinogen. After 60 min 
at 22~  wells were rinsed three times, and residual radioactivity 
quantified using a gamma counter. Nonspecific  fibrinogen binding 
was evaluated  in the presence of excess unlabeled fibrinogen. The 
specificity of mI-fibrinogen binding was further evaluated in the 
presence of 100/~M arginine, glycine, aspartic acid (ILGDS; Penin- 
sula Labs., Inc., Belmont, CA), or after platelet exposure to a mAb 
(20 #g/ml) recognizing the ellro/33 integrin, GPllb-IIIa (10E5, a 
gift from Dr. B. Coller) (24). 
Serotonin Release.  Platelets  were labeled with 14C-serotonin, 
5-hydroxy(side  chain-2-14C)tryptamine  creatinine sulphate (Amer- 
sham Corp., Arlington Heights, IL), in whole blood (25). 14C- 
serotonin release was measured at maximum platelet aggregation 
in the presence of 5/~M imipramine to prevent reuptake of  released 
serotonin. Samples were fixed with an equal volume of 2% for- 
malin, placed on ice, centrifuged for 3 min at 12,000 g, and the 
supernatant radioactivity evaluated in a beta counter. 
P-Selectin Expression.  The secretion of platelet c~ granules with 
concomitant expression of the platelet c~ granule membrane pro- 
tein designated P-selectin (CD62) was assessed after stimulating 
platelets with saturating concentrations of agg-Clq (100 #g/ml) 
(26) at 37~  for 10 rain. Platelet suspensions were subsequently 
fixed with paraformaldehyde  (27), washed, and exposed to a PE- 
labeled monoclonal antiCD62  antibody (Becton Dickinson Im- 
munocytometry Systems,  San Jose, CA) (30 rain, 22~  Platelets 
were washed three times in PBS and evaluated qualitatively for 
fluorescence at the Center for Imaging and Analysis (SUNY at 
Stony Brook) using a microscope/camera (Axiophot; Carl Zeiss, 
Inc., Thornwood, NY). Resting PGE1 (10 #M)-treated platelets, 
or platelets preincubated with 100 #g/ml monomeric Clq, served 
as negative  controls. Platelets  stimulated with 50 mU/ml thrombin 
(a gift from Dr. John Fenton II, New York State Department of 
Health, Albany, NY) served as positive controls. Thrombin was 
neutralized with excess hirudin before platelet fixation. 
lnositol-l,4,5-Triphosphate (IP3) Production.  WP  (2  x  109/ml) 
were incubated at 37~  in the presence of 0.1 mg/ml apyrase  and 
stimulated with 100/~g/ml agg-Clq. The reaction was terminated 
by adding 0.2 ml 1 M TCA per I ml of platelet suspension. After 
a  15-min incubation on ice, samples were centrifuged (1 rain, 
12,000 g, 4~  The supernatant (1 ml) was removed, and IP3 
quantified using an IP3 3H-radioreceptor assay kit (New England 
Nuclear Research Products, Boston,  MA)  as described by the 
manufacturer. 
Platelet Procoagulant Activity.  Platelet  factor 3 (PF3) availability 
was measured  by incubating 0.1 ml pooled normal plasma (George 
King Biomedical  Co., Overland Park, KS) with 0.1 ml kaolin (20 
580  Platelet  Activation  by Clq Table  1.  Inhibition of Agg-C1q Induced Film'nogen Binding 
to Platelets in Suspension and Fibrinogen Binding to Platelets 
Adhering to Clq-Coated Surfaces 
Inhibition of fibrinogen binding 
induced by: 
Inhibitor  Immobilized Clq  Agg-Clq 
% 
10E5  95  +_  7  ND 
KGDS  92  •  18  ND 
c-Clq  ND  85  +_  12 
II1/D1  ND  87  •  14 
6F1  ND  5  •  11 
Anti-Fc3/  KII  ND  7  •  9 
Anti-CD36/GPIV  ND  0  _+  8 
Platelets were preincubated (5 min, 22~  with inhibitors: 100 #g/ml 
c-Clq, 20 #g/ml 10E5, II1/D1, 6F1, or Anti-CD36,  50 #g/ml anti- 
Fc'y KII, or 100 #M RGDS. Platelets  were subsequently stimulated with 
25 #g/m1 agg-Clq in the presence of nsI-fibrinogen. Values represent 
mean _+ SD,  n  =  3. 
mg/ml) (Sigma  Chemical Co.). After 5 min at 37~  0.2 ml of 
platelets was added, followed by CaC12 (0.1 ml of a 0.035 M stock 
solution). Clot formation was monitored using a semi-automated 
impedance device (fibrometer; BBL, Division of Becton Dickinson 
& Co., Cockeysville,  MD). 
Results 
Platelet adhesion to Clq-coated  surfaces (59,000-68,000 
platelets/mm z) resulted in specific and saturable fibrinogen 
binding. Maximal binding was achieved after 60 min at 22~ 
Half-maximal binding  was  noted within  10 rain.  Binding 
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Figure  1.  Response  of WP to aggregated Clq (agg-Clq) in the pres- 
ence of 0.1 mg/ml fibrinogen. Aggregometer tracings depict the platelet 
response to 10 and 20 #g/ml agg-Clq in the presence or absence of 100 
/zg/ml c-Clq. 
was inhibited in the presence of 100 #M KGDS and preincu- 
bation of platdets with a mAb (10E5) recognizing the platdet 
membrane GPIIb-IIIa complex (Table 1). Assuming a 1:1 rela- 
tionship between bound fibrinogen and GPIlb-IIIa, Scatchard 
analysis (28) of fibrinogen binding isotherms revealed the ex- 
posure of 10,000 _+ 3,000 platelet membrane receptors, binding 
fibrinogen with  a Ka of 0.1  _+  0.03 #M  (n  =  3),  consis- 
tent with GPIIb-IIIa-fibrinogen interactions previously charac- 
terized in the fluid phase  (20). 
In  the  fluid phase,  platelet  exposure  to  Clq  multimers 
resulted in dose-dependent platelet aggregation (Fig. 1). Platdet 
aggregation in response to agg-Clq occurred without delay, 
and was  accompanied by t2sI-fibrinogen binding  and  14C- 
serotonin release (Table 2). Maximal fibrinogen binding was 
Table  2.  Washed  Platelet Responses to Agg-Clq:  Effect of Aspirin 
Platelets 
Stimulated with agg-Clq  Unstimulated 
Kesponse  ASA  Non-ASA  ASA  Non-ASA 
Aggregation (%)  64  _+  24  >90  0  0 
14C-serotonin  release  (%)  32  •  12  84  _+  18  0.4  _+ 0.2  0.1  _+  0.3 
Fibrinogen binding 
(molecules/platelet)  27,270  •  3690  41,240  +  1648  243  +_  124  285  •  58 
Platdet aggregation and serotonin release in response to 20 #g/m1 agg-Clq were measured 5 rain after stirring samples in an aggregometer at 37~ 
in the presence of 100 #g/m1 fibrinogen and 5 #M imipramine. Values are expressed as percent rdative to maximal aggregation or total platelet 
14C-serotonin,  respectively. Fibrinogen binding was measured 60 min after phtelet stimulation at 37~  in the presence of 250/zg/ml nsI-fibrino- 
gen without stirring. Unstimuhted  platelets served as controls. The responses of platdets pretreated with 1 mM aspirin (ASA) were compared to 
untreated platdets (Non-ASA). Data represent mean _+ SD,  n  =  5. 
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Figure 2.  lzsI-fibrinogen  binding to washed  platelets stimulated  with 
increasing concentrations  of agg-Clq or aggregated  IgG (agg-IgG). WP 
were  incubated  with agg-Clq or agg-IgG  for 60 min at 22~  in the pres- 
ence of 250/~g/m112sI-fibrinogen.  Fibrinogen  binding was quantified  as 
described in Materials and Methods. 
obtained in the presence of 30-75/zg/ml agg-Clq (Fig.  2). 
Fibrinogen binding to phtelets in suspension was always higher 
than fibrinogen binding to platelets adhering to Clq-coated 
surfaces.  This may reflect the extent of platdet stimulation 
and/or the potentially decreased accessibility  of fibrinogen 
receptors on adherent platdets which bind fibrinogen only 
to their nonadherent surface. Platelet aggregation, fibrinogen 
binding,  and  serotinin  release  were  all  inhibited but  not 
abrogated after pretreatment of platdets with 1 mM aspirin, 
confirming the involvement of cyclo-oxygenase-dependent 
synthesis  of thromboxane  A2  (29)  and  release  of platelet 
granule contents. The release of ot granules was inferred from 
qualitative analysis of cell surface P-selectin expression by di- 
rect immunofluorescence (Fig.  3).  Interestingly, the extent 
of P-selectin expression by 100 Ixg/ml agg-Clq  (Fig.  3 E) 
appeared similar to that noted after platelet stimulation with 
a standard dose of thrombin  (Fig.  3 F). 
To rule out platelet activation via occupancy of FcyRII 
receptors  (30)  by  potential  trace agg-IgG  contamination, 
fibrinogen binding was compared in response to agg-Clq or 
similar concentrations of agg-IgG.  As summarized in Fig. 
2, agg-IgG was without effect at 22~  in unstirred systems. 
Moreover, agg-Clq-induced fibrinogen binding was inhibited 
in the presence of the collagen-like NH2-terminal domain 
of Clq (c-Clq) or mAbs (II1/D1) directed against the 67-kD 
Clq receptor (Table  1).  mAbs directed against the FcyRII 
receptor, the VLA-2 collagen receptor, or CD36/GPIV, also 
reported to function in platelet-collagen interactions (31), 
were without effect (Table  1). 
Platelet stimulation with agg-Clq was associated with rapid 
IP3 production (Fig. 4). To optimize IP3 generation, platelets 
were stimulated with 100 #g/ml agg-Clq. The reaction was 
terminated at 2, 15, and 30 s. Maximal IP3 production was 
observed within 15 s of platelet stimulation (Fig. 4). By 30 s, 
IP3 levels decreased almost to baseline. 
Platelet stimulation with agg-Clq was also accompanied 
by the expression of surface membrane procoagulant activity. 
As  summarized  in  Table  3,  shortening  of  the  kaolin 
recaldfication time of pooled normal plasma was observed 
in the presence of platelets activated with increasing concen- 
trations of agg-Clq.  Clotting times in the presence of un- 
Fig'are 3.  Phase contrast views of 
unstimulated  (.4) phtdets and platelets 
stimulated with 100/~g/ml agg-Clq 
(B), or 50 mU/ml human thrombin 
(63. Immundhorescence  views  demon- 
strating P-selectin expression on un- 
stimulated  phtdets (D), phtdets stimu- 
lated with 100/~g/ml  agg-Clq (E), or 
50 mU/ml thrombin (F) using a PE- 
conjugated anti CD-62 mAb. Same 
views as 3 A-C.  x200. 
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as negative and positive controls,  respectively. 
Discussion 
Clq receptors are present on numerous somatic and cul- 
tured cells where they mediate a variety of cell-specific reac- 
tions (4). Platelets possess *4,000 Clq binding sites per cell 
and bind Clq  with  a Kd of 3.5  x  10 -7  M  in  a  divalent 
cation independent manner (26).  The present study charac- 
terizes platelet responses to agg-Clq in solution and to im- 
mobilized Clq on plastic surfaces. The data demonstrate the 
direct involvement of the 67-kD phtelet ClqR in Clq-induced 
583  Peerschke  et al. platelet stimulation.  This stimulation involves several surface 
membrane-associated  events including IP3 production, acti- 
vation of GPIIb-IIIa fibrinogen receptors, cyclo-oxygenase- 
mediated thromboxane A2 formation supporting the release 
of platelet granule contents, and the expression of P-selectin 
and procoagulant activity. 
Previous studies (9, 10) have described the interaction of 
soluble Clq monomers with human platelets. The structural 
584  Platelet  Activation  by Clq similarity between Clq and collagen suggested a potential 
role for platdet Clq receptors in modulating collagen-induced 
platelet functions. Interestingly, studies with highly purified 
Clq monomers and monodonal as well as polyclonal  anfi-ClqR. 
antibodies demonstrated that whereas Clq and anti-ClqR 
antibodies inhibited collagen-induced  platelet aggregation and 
secretion at low concentrations of  collagen, they did not affect 
the adhesion of platelets to collagen fibrils or collagen-coated 
surfaces (32). Moreover, the effect of anti ClqR Abs and an 
Ab directed against the platelet VLA-2 receptor dearly indi- 
cated that platelet adhesion to Type I collagen and Clq was 
mediated by distinct receptors (12). This concept is further 
supported by observations made in the present study demon- 
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Figure 4.  IP3 production 15 and 30 s after phtelet stimulation 07~ 
with 100/zg/ml agg-Clq (open  ban) or 0.5 mU/ml human  thrombin  (hatched 
ba~). Baseline IP3 l~els were established using umtimuhted phtelets (fil/ed 
bar), incubated with 10/~M PGE1. Error bars depict one SD. 
Table  3.  Effect  of  Platelet Stimulation with Agg-C1q on the Kaolin 
Recakification Time  of Normal Pooled Plasma 
Addition  Clotting time 
$ 
Buffer  114  _+  13 
Resting platelets  108  +  9 
Phtdets  +  Thrombin  56  _+  15 
Platelets  +  Agg-Clq 
20 ~g/ml  92  _+  12 
30 ~g/ml  78  _+  11 
100 lzg/ml  62  _+  14 
Washed phtdets were stimulated with 0.10 U/m1 human thrombin or 
agg-IgG (20-100 ~g/ml). Thrombin was neutralized with excess hirudin 
before adding 0.2 ml of the platelet suspension to 0.2 ml normal plasma 
preincubated  5 min (370C) with 10 mg/ml kaolin. Clotting was initi- 
ated by adding 0.1 ml CaClz (0.035 M). Values represent mean _+ SD, 
n  =  3. 
585  Peerschke  et al. ulation by anti ClqK antibodies, whereas anti-VLA-2 Abs 
and Abs against the CD36 collagen receptor were without 
effect. 
Since circulating platelets are more likely to encounter Clq 
multimers (14) or Clq immobilized to extraceUular matrix 
components (15) than Clq monomers, the ability of agg- 
Clq and Clq coated sttrfaces to activate phtdets provides strong 
support for the hypothesis that occupancy of the ClqR may 
contribute to thrombotic events associated with complement 
activation and inflammation. For example, platelet aggrega- 
tion is the sine qua non for hemostatic or thrombotic platelet 
plug formation. Platelet aggregation requires occupancy of 
surface membrane agonist receptors capable of signal trans- 
duction. The present study suggests that the platelet ClqK 
may be such a receptor, as ClqR occupancy was associated 
with rapid IP3 formation. IP3 is an intracellular messenger 
that serves to raise cytosolic calcium (33).  Increases in in- 
traplatelet calcium levels are associated with changes in phtelet 
membrane GPIIb-IIIa expression from an inactive to an ac- 
tive conformation. Indeed, platelet activation with agg-Clq 
or immobilized Clq in the present study was accompanied 
by specific  and saturable fibrinogen binding.  This bound 
fibrinogen is thought to be primarily responsible for platelet 
cohesion. 
Platelet stimulation by agg-Clq was also accompanied by 
the release of platelet-dense granule serotonin, o~ granule secre- 
tion was inferred from cell surface P-selectin expression. Dense 
bodies contain not only serotinin, but also ADP which is 
an important agonist and may function to attract additional 
platelets to the site of a growing thrombus by expression of 
active GPIIb-IIIa complexes (34).  In addition, dense bodies 
contain biogenic amines that may participate in inflamma- 
tory reactions. In contrast, the release of ot granule contents 
includes a number of adhesive proteins such as fibrinogen, 
fibronectin, and thrombospondin, that may serve to reinforce 
phtelet-platelet interactions (35). Secretion of ot granule con- 
tents is also accompanied by the surface expression of an c~ 
granule membrane protein, P-sdectin, previously referred to 
as GMP 140 or PADGEM (36, 37). P-selectin has been shown 
to mediate the adhesion of nentrophils and monocytes to ac- 
tivated platelets in a calcium-dependent manner (37). 
Platelet ct granule secretions also contain the active form 
of coagulation factor V (Va) (38). This, in combination with 
surface membrane changes leading to the exposure of nega- 
tively charged phospholipids (phosphatidylserine, phospha- 
tidylinositol), encompasses PF3 procoagulant activity (39). 
PF3  activity is  essential for efficient thrombin generation 
leading to fibrin clot formation. Indeed, exposure ofplatelets 
to agg-Clq in the present study lead to dose-dependent PF3 
generation, as measured by the kaolin recalcification time, 
a standard assay for the evaluation of platelet procoagnlant 
activity (40). 
Since platelet Clq receptors were previously found to par- 
ticipate in immune complex localization via immune com- 
plex association with the globular head region of Clq (41), 
the question arises as to whether ClqK occupancy by the 
coUagen-like NH2-terminal region of Clq is physiologically 
beneficial or detrimental. Based on available data, low con- 
centrations of Clq multimers (<5-10 #g/ml), formed after 
binding immune complexes, certain bacteria or viruses,  may 
participate in clearance mechanisms, and/or antigen presen- 
tation to lymphoid cells of the reticuloendothelial system. 
In contrast, high concentrations of agg-Clq appear likely to 
contribute to thrombotic and inflammatory reactions. 
The authors are grateful to Joan Hennessey and Jean A. Wainer for expert technical assistance. 
This work was supported in part by grants 900994 (E.I.B. Peerschke and B. Ghebrehiwet) sponsored by 
the American Heart Association-Wyeth  Ayerst  Laboratories, and 900696 (B. Ghebrehiwet) from the American 
Heart Association (Dallas, TX). 
Address correspondence to Dr. Ellinor I. Peerschke, University Hospital, L-3, State University of New 
York at Stony Brook, Stony Brook, NY 11794-7300. 
Received for publication 16 February 1993 and in revised form 23 April  1993. 
References 
1.  Lepow, I.H., G.B. Naff, E.W. Todd, J. Pensky, and C.F. Hinz. 
1963. Chromatographic resolution of the first component of 
human complement with three activities.J. Exl~ Med. 117:983. 
2.  Ziccardi, K.J., and N. Cooper. 1977. The subunit composi- 
tion and composition properties of human C1. J. Immunol. 
118:2047. 
3.  sire, K.B., G.J. Arlaud, and M.G. Colomb. 1979. C1 inhib- 
itor dependent dissociation of human complement component 
C1 bound to immune complexes. Biochem. J.  179:449. 
4.  Ghebrehiwet,  B.  1987. Clq receptor. In Methods in Enzy- 
586  Platelet  Activation  by Clq 
5. 
6. 
mology. G. DiSabato, editor. Vol. 150, Academic Press, Inc., 
San Diego. 558-568. 
Lindgren, S., A.B. Laurell, and S. Eriksson. 1984. Comple- 
ment components and activation in primary biliary cirrhosis. 
Hematology. 4:9. 
Kossen, K.D., J.L. Swain, L.H. Michael, S. Weakly, E. Gian- 
nini, and M.L. Entman. 1985. Selective accumulation of the 
first component of complement and leukocytes in ischemic ca- 
nine heart muscle: a possible initiator  of an extramyocardial 
mechanism of ischemic injury. Cir~ Res. 57:119. 7.  Bensa,  J.C., A. Revoul, and M.G. Colomb. 1983. Biosynthesis 
in vitro of complement subcomponent Clq, Cls and C1 in- 
hibitor by resting and stimulated human monocytes. Biochem. 
J. 216:385. 
8.  Tennner, A.J., and D.B. Volkin. 1986. Complement subcom- 
ponent Clq secreted  by cultured monocytes has subunit struc- 
ture identical with that of serum Clq. Biochem. J. 233:451. 
9.  Cazenave,  J.P., S.N. Assimeh, R.H. Painter, M.A. Packham, 
and J.E Mustard. 1976. Clq inhibition of the interaction of 
collagen with human platelets, f  Immunol. 116:162. 
10.  Csako, G., and E.A. Suba. 1987. Free platelet count and size 
distribution during Clq inhibition of  coUagen-induced  platelet 
aggregation.  Thromtx Haemostasis. 58:682. 
11.  Reid,  K.B.M.  1989. Clq:  genes, biosynthesis and biology. 
Behring Inst. Mitt. 84:8. 
12.  Peerschke, E.I.B., and B.  Ghebrehiwet.  1990. Platelet Clq 
receptor interactions with collagen and Clq coated surfaces. 
J. lmmunol. 145:2984. 
13.  Hughes-Jones, N.C., and B. Gardner. 1978. The reaction be- 
tween the complement subcomponent Clq, IgG complexes, 
and polyionic molecules. Immunology. 34:459. 
14.  Cooper, N.R., and D.C. Morrison. 1978. Binding and activa- 
tion of the first component of  human complement by the lipid 
A region of lipopolysaccharides,  f  Immunol. 120:1862. 
15.  Bordin, S., B. Ghebrehiwet, and R.C. Page. 1990. participa- 
tion of Clq and its receptor in adherence of human diploid 
fibroblasts. J. Immunol. 145:2520. 
16.  Tangen, O., M.L. Andrae, and B.E. Nilssen. 1973. Nucleotide 
leakage from platelets  in artificial  media: prevention  by albumin 
and other macromolecules  and relation to ADP-induced  platelet 
aggregation. &and. f  HaematoL 11:241. 
17.  Reid, K.B.M. 1981. Preparation of human Clq, a subcompo- 
nent of the first component of the classical  pathway of com- 
plement. Methods Enzymol. 80:16. 
18.  Reid, K.B.M. 1976. Isolation, by partial pepsin digestion, of 
the three collagen-like  regions present in subcomponent Clq 
of the first  component of  human complement.  Biochem.J. 155:5. 
19.  Ghebrehiwet, B., B.P. Randazzo, J.T. Dunn, M.S. Silverberg, 
and A.P. Kaplan. 1983. Mechanisms of activation of the clas- 
sical pathway of complement by Hageman factor fragment. 
J.  Clin. Invest. 71:1450. 
20.  Peerschke, E.I.B., M.B. Zucker, R.A. Grant, J.J. Egan, and 
M.M. Johnson. 1980. Correlation between fibrinogen binding 
to human platelets and platelet aggregability. Blood. 55:841. 
21.  Ghebrehiwet, B. 1986. Production and characterization of a 
murine monoclonal IgM antibody to human Clq receptors 
(ClqR). J. Immunol. 137:618. 
22.  CoUer,  B.S.,  J.H. Beer, L.E. Scudder, and M.H. Steinberg. 1989. 
Coilagen-platelet interactions: evidence  for a direct interaction 
of collagen with platelet GPIa/IIa and an indirect interaction 
with platelet GPIIb/IIIa mediated by adhesive  proteins. Blood. 
74:182. 
23.  Tuszynski, G.P., and A. Murphy. 1990. Spectrophotometric 
quantitation of anchorage dependent cell numbers using bi- 
cinchoninic acid protein assay  reagent. Anal. Biochem. 184:189. 
24.  Coiler, B.S., E.I. Peerschke, L.E. Scud&r, and C.A. Sullivan. 
1983. A murine monoclonal antibody that completely blocks 
the binding of fibrinogen to platelets produces a thrombas- 
thenic-like state in normal platelets and binds GPlIb and/or 
GPIIIa. f  Clin. Invest. 72:325. 
25.  Peerschke"  E.I. 1982. Induction of human platelet fibrinogen 
receptors by epinephrine in the absence of  released ADP. Blood. 
60:71. 
26.  Peerschke, E.I.B., and B. Ghebrehiwet. 1987. Human blood 
platelets possess specific binding  sites for Clq. J. Immunol. 
138:1537. 
27.  Du, X., E. Plow, A. Frelinger, T. O'Toole, J. Loftus, and M. 
Ginsberg.  1991. Ligands  "activate" integrin  alphalro/beta~ 
(platelet GPIIb-IIIa). Cell. 65:409. 
28.  Scatchard, G. 1949. The attraction of proteins for small mole- 
cules and ions. Ann.  NY A_cad. Sci. 51:660. 
29.  Quick, A.J. 1966. Salicylates  and bleeding: the aspirin toler- 
ance test. Am. f  Med. Sci. 252:265. 
30.  Kelton, J.G., J.W. Smith, A.V. Santos, W.G. Murphy, and P. 
Horsewood. 1987. Platelet IgG Fc receptor. Am.f Hematol. 
25:299. 
31.  Tandon, N.N., U. Kralisz, and G.A. Jamieson. 1989. Identi- 
fication of glycoprotein IV (CD36) as a primary receptor for 
platelet collagen adhesion. J. Biol. Chem. 264:7576. 
32.  Peerschke, E.I.B., and B. Ghebrehiwet. 1990. Modulation of 
platdet responses to collagen by Clq receptors. J. Immunol. 
144:221. 
33.  Brass,  L.F., D.R. Manning, and S.J. Shattil. 1991. GTP-binding 
proteins and platelet activation. In Progress in Hemostasis and 
Thrombosis, Vol. 10. B.S. Coiler, editor. W.B. Saunders Co., 
Philadelphia. 127-174. 
34.  Peerschke,  E.I.B. 1985. The platelet fibrinogen receptor. Sere. 
Hematol. 22:241, 
35.  Mosher, D.F., D.M. Pesciotta,  J.C. Loftus, and R.W. Albrecht. 
1985. Secreted alpha granule proteins: the race for receptors. 
In Phtelet Membrane  Glycoproteins.  J.N. George, A.T. Nurden, 
and D.R. Phillips, editors. Plenum Press, New York. 171-191. 
36. Johnston, G.I., G.A. Bliss, p.J. Newman, and R.P. McEver. 
1990. Structure of the human gene encoding granule mem- 
brane protein GMP 140, a member of the selectin family of 
adhesion receptors for leukocytes,  f  Biol. Chem. 265:21381. 
37.  Larsen, E., A. Celi, G.E. Geibert, B.C. Furie, J.K. Erban, R. 
Bonfanti, D. Wagner, and B. Furie. 1989. PADGEM protein: 
a receptor that mediates the interactions of activated platelets 
with neutrophils and monocytes. Cell. 59:305. 
38.  Holmsen,  H.  1982. Platelet secretion. In  Hemostasis and 
Thrombosis.  Basic Principles and  Clinical Practice. R.W. 
Colman, J. Hirsch, V.J. Marder, and E.W. Salzman, editors. 
J.B. Lippincott Co., Philadelphia. 390--403. 
39.  Zwaal, R.EA. 1978. Membrane and lipid involvement  in blood 
coagulation. Biochim. Biophys. Acta. 515:163. 
40.  Hardisty, R.M., and R.A. Hutton. 1965. The kaolin clotting 
time of platelet-rich plasma: a test of platelet factor-3 avail- 
ability. Br. f  Haematol. 11:258. 
41.  Peerschke,  E.I.B., and B. Ghebrehiwet. 1992, Platelet interac- 
tions with Clq in whole blood and in the presence of  immune 
complexes or aggregated IgG. Clin. Immunol. Immunopathol. 
63:45. 
587  Peerschke  et al. 